Multiple Sclerosis PBMC

Multiple Sclerosis PBMC for Neuroimmunology and Autoimmunity Research

Multiple Sclerosis (MS) Human PBMC are sourced from IRB-consented donors clinically diagnosed with MS, processed within 24 hours of collection and cryopreserved in CryoStor® CS10. MS is an autoimmune disease of the central nervous system in which lymphocytes cross the blood-brain barrier and drive demyelination and axonal loss. Because the pathogenic cells originate in and traffic through the blood, cryopreserved peripheral blood mononuclear cells are the workhorse specimen for MS immunology and drug development.

Why PBMC for Multiple Sclerosis

Nearly every approved disease-modifying therapy in MS acts on a peripheral blood leukocyte — by depleting it, sequestering it, or blocking its migration. That makes PBMC not merely a convenient surrogate but the actual target compartment.

• Myelin-reactive T cells — CD4+ Th1 and Th17 cells reactive to myelin antigens are central to MS pathogenesis, and PBMC support antigen-specific stimulation, proliferation and cytokine recall assays that cannot be done in serum or plasma.
• B cells are pathogenic, not incidental — the striking efficacy of anti-CD20 therapy established B cells as central to MS. PBMC allow memory B-cell phenotyping, depletion pharmacodynamics and repopulation kinetics to be measured directly.
• Lymphocyte trafficking mechanisms — natalizumab blocks alpha-4 integrin (VLA-4) and S1P receptor modulators trap lymphocytes in lymph nodes; both mechanisms are assayed on intact PBMC through adhesion, migration and receptor-expression readouts.
• Regulatory T-cell function — impaired regulatory T-cell suppressive capacity is a recurring finding in MS and requires live, functional cells to test.
• CD8+ T cells and tissue-resident phenotypes — CD8+ T cells dominate MS lesions, so circulating CD8 differentiation and clonality are informative, particularly alongside TCR sequencing.
• Epstein-Barr virus biology — the strong epidemiologic link between EBV infection and MS is investigated using EBV-specific T-cell and B-cell responses, which requires viable PBMC for antigen recall assays.

Donor Stratification Available

• Disease course: relapsing-remitting, secondary progressive, or primary progressive MS
• Clinical state at collection: active relapse versus clinical remission
• Disability level: EDSS score where recorded, and disease duration since diagnosis
• Disease-modifying therapy: treatment-naive, interferon beta, glatiramer acetate, dimethyl fumarate, S1P modulator, natalizumab, anti-CD20 therapy, or cladribine
• Recent corticosteroid exposure and time since last dose, which materially affects immune phenotype
• Matched healthy controls available, age- and sex-matched on request

Product Features

• Research Use Only (RUO), cryopreserved PBMCs
• Clinically confirmed MS donors
• Available in cell counts ranging from 5 million to 2 billion
• Processed within 24 hours of collection
• Stored using CryoStor® CS10 freezing media
• Viability and recovery reported per lot
• IRB-approved protocols and electronic informed consent
• Screen LeukoLot™ available prior to bulk orders

De-identified Donor Data

• Verified MS diagnosis, including disease course where available
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported allergies, medications and infectious disease history
• EDSS, relapse history and treatment history where recorded
• Additional MS-specific data available upon request

Applications

• Antigen-specific T-cell stimulation, proliferation and cytokine recall assays
• Deep immunophenotyping of T-cell, B-cell and monocyte compartments
• Memory B-cell and anti-CD20 pharmacodynamic and repopulation research
• Lymphocyte adhesion, migration and integrin blockade assays
• Regulatory T-cell functional suppression studies
• TCR and BCR repertoire sequencing
• Single-cell RNA-seq and CITE-seq of the MS immune compartment
• Drug screening, mechanism-of-action and biomarker discovery for disease-modifying therapies

Other Multiple Sclerosis Specimen Types

• Multiple Sclerosis Serum
• Multiple Sclerosis Plasma
• Multiple Sclerosis Whole Blood
• Multiple Sclerosis Leukopak
• Multiple Sclerosis Cerebrospinal Fluid
• Relapsing-Remitting MS PBMC and Secondary Progressive MS PBMC

Compliance and Quality Assurance

• IRB-approved collections and protocols
• 21 CFR Part 11 – compliant e-consent system
• HIPAA-compliant donor data protection

Ordering & Customization

Multiple Sclerosis PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, availability or a specific stratification request, email learnmore@sanguinebio.com; please also contact us for international orders or regulatory documentation needs. To browse availability across all disease states, visit our human PBMC page.